Trial Search Results
Transplantation for Patients With Chronic Lymphocytic Leukemia
To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell transplantation for the treatment of chronic lymphocytic leukemia.
Stanford is currently not accepting patients for this trial.
- Procedure: high dose chemotherapy then autologous hematopoietic cell transplant
- Procedure: ablative allogeneic hematopoietic cell transplant
Inclusion Criteria:- adequate organ function
- normal bone marrow cytogenetics Exclusion Criteria:- active CNS disease
- For autologous patients more than 30% bone marrow involvement
Ages Eligible for Study
18 Years - 60 Years
Genders Eligible for Study